PE20070790A1 - Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4 - Google Patents

Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4

Info

Publication number
PE20070790A1
PE20070790A1 PE2006001110A PE2006001110A PE20070790A1 PE 20070790 A1 PE20070790 A1 PE 20070790A1 PE 2006001110 A PE2006001110 A PE 2006001110A PE 2006001110 A PE2006001110 A PE 2006001110A PE 20070790 A1 PE20070790 A1 PE 20070790A1
Authority
PE
Peru
Prior art keywords
alkyl
histamine
amino
modulators
receptor activity
Prior art date
Application number
PE2006001110A
Other languages
English (en)
Inventor
Gonzalez Elena Carceller
Solana Jorge Salas
Soliva Robert Soliva
Fuentes Eva Maria Medina
Via Josep Marti
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of PE20070790A1 publication Critical patent/PE20070790A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DE 2-AMINOPIRIMIDINA DE FORMULA(I), EN DONDE R1 ES SELECCIONADO DE a), b), Y c); R2 ES H O ALQUILO(C1-C4); R3 ES FENILO OPCIONALMENTE FUSIONADO A UN ANILLO DE 5 O 6 MIEMBROS PUDIENDO SER CARBOCICLICO O HETEROCICLO TAL COMO NAFTILO, OPCIONALMENTE SUSTITUIDOS POR R8; R4, R5, R6 Y R7 SON INDEPENDIENTEMENTE H O ALQUILO(C1-C4); R8 ES ALQUILO(C1-C47), HALOGENO, HALOALCOXI(C1-C4), -CN O ALQUINILO(C2-C4); m ES 1,2 O 3; n ES 0 O 1; Y p ES 1 O 2. SON PREFERIDOS: 2-AMINO-4-CLORO-6-(4-METILPIPERAZIN-1-IL)PIRIMIDINA, [(3R)-1-(2-AMINO-6-CLOROPIRIMIDIN-4-IL)PIRROLIDIN-3-IL]CARBAMATO DE TERC-BUTILO, 2-AMINO-4-(4-CLOROFENILAMINO)-6-(4-METIL-[1,4]DIAZEPAN-1-IL)PIRIMIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMEINTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS PRESENTAN ACTIVIDAD MODULADORA DEL RECEPTOR DE HISTAMINA H-4, POR LO QUE SON UTILES EN EL TRATAMIENTO DE UNA ENFERMEDAD INMUNOLOGICA O INFLAMATORIA
PE2006001110A 2005-09-13 2006-09-13 Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4 PE20070790A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05380195 2005-09-13
EP06381027 2006-06-09

Publications (1)

Publication Number Publication Date
PE20070790A1 true PE20070790A1 (es) 2007-08-24

Family

ID=37596549

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001110A PE20070790A1 (es) 2005-09-13 2006-09-13 Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4

Country Status (14)

Country Link
US (1) US20090306038A1 (es)
EP (1) EP1928862A1 (es)
JP (1) JP2009507896A (es)
KR (1) KR20080043840A (es)
AR (1) AR056511A1 (es)
AU (1) AU2006290715A1 (es)
BR (1) BRPI0615880A2 (es)
CA (1) CA2622372A1 (es)
IL (1) IL189947A0 (es)
NO (1) NO20081003L (es)
PE (1) PE20070790A1 (es)
RU (1) RU2008114378A (es)
TW (1) TW200800956A (es)
WO (1) WO2007031529A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
NZ571691A (en) 2006-03-31 2011-07-29 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
CN103450077B (zh) 2007-06-08 2016-07-06 满康德股份有限公司 IRE-1α抑制剂
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
WO2009068512A1 (en) * 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
TW200940529A (en) * 2007-12-19 2009-10-01 Palau Pharma Sa 2-amino-pyrimidine derivatives
US8431580B2 (en) * 2007-12-21 2013-04-30 Palau Pharma, S.A. 4-aminopyrimidine derivatives as histamine H4 receptor antagonists
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
BRPI0915526A2 (pt) * 2008-06-12 2016-01-26 Janssen Pharmaceutica Nv uso de um antagonista da histamina h4 para o tratamento de aderências pós-operatórias
BRPI0915720A2 (pt) 2008-06-12 2015-08-04 Janssen Pharmaceutica Nv Moduladores de diaminopiridina, pirimidina, e piridazina do receptor de histamina h4
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
UA107818C2 (en) 2009-12-23 2015-02-25 Medicis Pharmaceutical Corp Usa Alkyl amino pyrimidine derivatives as antagonists district h4-histamine receptors
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
JP6185574B2 (ja) 2012-06-08 2017-08-23 センソリオン 耳鳴りを治療するためのｈ４受容体阻害剤
UY35370A (es) 2013-03-06 2014-09-30 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4
EP3055301B1 (en) * 2013-10-07 2019-11-20 Kadmon Corporation, LLC (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine derivatives as rho kinase inhibitors for treating autoimmune diseases
CN105829293B (zh) * 2013-12-20 2018-11-09 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
CN112625028A (zh) 2015-06-19 2021-04-09 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
EP3310771B1 (en) 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
MX2018015625A (es) 2016-06-14 2019-03-06 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
EP3562811B1 (en) 2016-12-29 2022-03-16 Minoryx Therapeutics S.L. Heteroaryl compounds and their use
US10172856B2 (en) 2017-04-06 2019-01-08 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine H4 modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1242385B1 (en) * 1999-12-28 2009-11-25 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
EP1505064A1 (en) * 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
US20070021435A1 (en) * 2005-06-10 2007-01-25 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281764A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.

Also Published As

Publication number Publication date
RU2008114378A (ru) 2009-10-20
IL189947A0 (en) 2008-08-07
BRPI0615880A2 (pt) 2011-05-31
AU2006290715A1 (en) 2007-03-22
NO20081003L (no) 2008-04-11
JP2009507896A (ja) 2009-02-26
KR20080043840A (ko) 2008-05-19
AR056511A1 (es) 2007-10-10
CA2622372A1 (en) 2007-03-22
TW200800956A (en) 2008-01-01
WO2007031529A1 (en) 2007-03-22
US20090306038A1 (en) 2009-12-10
EP1928862A1 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
PE20070790A1 (es) Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4
AR054799A1 (es) Derivados de oxindol
PE20211918A1 (es) Derivados de tetrahidro-imidazo[4,5-c]piridin como inmunomoduladores de pd-l1
PE20221038A1 (es) Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20091095A1 (es) Moduladores de gamma secretasa
EA200970326A1 (ru) Алкильные производные в качестве метаботропных рецепторов глутамата
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20060837A1 (es) COMPUESTOS DE 3H-OXAZOLO Y 3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA 3,5-DISUSTITUIDA Y 3,5,7-TRISUSTITUIDA Y PROFARMACOS DE LOS MISMOS
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
MA31766B1 (fr) Composés organiques
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
PE20130242A1 (es) Derivados de isoxazolo-piridina
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
PE20040168A1 (es) Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed